Using Medicare administrative data to conduct postmarketing surveillance of follow-on biologics: issues and opportunities

MeSH terms

• Biological Products / adverse effects*
• Biological Products / therapeutic use
• Drug Approval / methods*
• Healthcare Common Procedure Coding System
• Humans
• Insurance Claim Reporting
• International Classification of Diseases
• Investigational New Drug Application / methods*
• Medicare*
• Product Surveillance, Postmarketing / methods*
• Therapeutic Equivalency
• United States